Live video webcast presentation on Friday, February 18th at 10:40 AM ET
ISELIN, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President & Chief Executive Officer will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 10:40 AM ET.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live video webcast of the presentation will be available on the Events page of the Investors section of Outlook Therapeutics’ website (outlooktherapeutics.com). A webcast replay will be available following the live presentation and will be accessible for 90 days.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.
LaVoie Health Science
Chief Executive Officer
JTC Team, LLC
Source: Outlook Therapeutics, Inc.